Showing results (171-180 of 438) with videos related to

Sort By:
Pageof 44
JCO Clinical Cancer Informatics|July 17, 2024
Predicting Benefit From FOLFOXIRI Plus Bevacizumab in Patients With Metastatic Colorectal CancerMarinde J G Bond, Maarten van Smeden, Koen Degeling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2021
Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA)J Randolph Hecht, Sara Lonardi, Johanna Bendell, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|February 27, 2026
Multidisciplinary approach to bone metastases: a single center experience in a tertiary cancer centerChiara Pittarello, Antonella Brunello, Evelina Lamberti, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2023
Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitorsPaolo Manca, Francesca Corti, Rossana Intini, et al.
British Journal of Cancer|February 12, 2024
HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES studyAlessandra Anna Prete, Valentina Angerilli, Francesca Bergamo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 8, 2024
Gastric Carcinoma in Autoimmune Gastritis: A Histopathologic and Molecular StudyValentina Angerilli, Alessandro Vanoli, Giulia Celin, et al.
European Journal of Cancer (Oxford, England : 1990)|March 18, 2022
Prognostic impact of FGFR2/3 alterations in patients with biliary tract cancers receiving systemic chemotherapy: the BITCOIN studyMario Rizzato, Stefano Brignola, Giada Munari, et al.
European Journal of Cancer (Oxford, England : 1990)|July 1, 2022
Prognostic impact of performance status on the outcomes of immune checkpoint inhibition strategies in patients with dMMR/MSI-H metastatic colorectal cancerGiacomo Mazzoli, Romain Cohen, Sara Lonardi, et al.
Journal of Cancer Research and Clinical Oncology|November 7, 2019
Clinical impact of first-line bevacizumab plus chemotherapy in metastatic colorectal cancer of mucinous histology: a multicenter, retrospective analysis on 685 patientsVincenzo Catalano, Francesca Bergamo, Chiara Cremolini, et al.
European Journal of Cancer (Oxford, England : 1990)|November 6, 2022
The oncological multidimensional prognostic index is a promising decision-making tool: A real-world analysis in older patients with metastatic colorectal cancerLetizia Procaccio, Francesca Bergamo, Maura Gatti, et al.
Pageof 44